Stem Pharm's synthetic biomaterials support the optimization of cell expansion.
Stem Pharm was founded in 2015 with the purpose of being a trusted supplier of synthetic biomaterials that are specifically designed to meet customer's requirements as they develop more advanced cellular models for drug discovery and toxicity screening and cellular therapies for regenerative medicine applications. Stem Pharm is located in the Fitchburg Technology Campus, near the University of Wisconsin campus. It Leverages its expertise in biomaterials and cellular interactions to develop high-value applications of organoids (3-D in vitro models) for drug discovery and cell-friendly coatings for the manufacture of-cell based therapies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 20, 2017 | Grant | $290K | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |